LCTX
Lineage Cell Therapeutics Inc
0.9274$
-0.3%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | -5.7% | -143.8% | – | – | – | – | – | – | – | – | – | – | – | 25.7% | 27.7% | 43.0% | 43.7% | 15.9% | 9.4% | 21.3% | 27.9% | 49.8% | 36.6% | 5.0% | 7.5% | 3.5% | 5.8% | |
| 100.0% | 100.0% | 100.0% | 105.7% | 243.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 74.3% | 72.3% | 57.0% | 56.3% | 84.1% | 90.6% | 78.7% | 72.1% | 50.2% | 63.4% | 95.0% | 92.5% | 96.5% | 94.2% | |
| 2,100.0% | 2,100.0% | 566.7% | 472.3% | 6,406.4% | 1,109.3% | 285.1% | 162.3% | 163.2% | 168.9% | 122.4% | 92.5% | 113.5% | 154.2% | 214.4% | 314.6% | 1,070.2% | 930.1% | 1,928.3% | 1,681.3% | 1,603.3% | 1,340.6% | 1,479.9% | 1,214.3% | 1,593.4% | 870.5% | 95.1% | 175.6% | 131.3% | 121.8% | |
| 1,200.0% | 1,200.0% | 400.0% | 182.8% | 3,390.9% | 1,291.1% | 340.6% | 226.6% | 215.6% | 154.6% | 128.4% | 124.3% | 174.2% | 128.6% | 153.3% | 214.5% | 612.3% | 543.8% | 902.0% | 1,149.7% | 1,262.3% | 1,111.7% | 1,746.2% | 1,625.9% | 2,014.4% | 467.5% | 153.1% | 193.4% | 191.3% | 126.8% | |
| 2,100.0% | 3,300.0% | 800.0% | 660.9% | 9,941.0% | 2,400.3% | 625.7% | 403.7% | 386.0% | 323.5% | 250.8% | 216.8% | 287.7% | 282.9% | 367.7% | 529.1% | 1,551.2% | 1,418.9% | 2,660.9% | 2,653.4% | 2,702.5% | 2,359.4% | 2,973.8% | 2,702.4% | 3,471.5% | 1,326.5% | 248.2% | 369.0% | 322.6% | 243.8% | |
| -2,000.0% | -3,200.0% | -700.0% | -555.2% | -9,697.2% | -2,300.3% | -525.7% | -303.7% | -286.0% | -223.5% | -150.8% | -116.8% | -187.7% | -182.9% | -267.7% | -429.1% | -1,476.8% | -1,956.8% | -2,604.0% | -2,597.0% | -2,618.4% | -2,170.9% | -2,951.6% | -2,630.3% | -3,421.3% | -1,263.1% | -153.2% | -276.5% | -226.1% | -149.6% | |
| 0.0% | 200.0% | 0.0% | 27.0% | 314.8% | 75.3% | 5.3% | 196.0% | 4.7% | 8.7% | 13.5% | 1.6% | 64.2% | 85.9% | 3.4% | 4.9% | 18.0% | 911.9% | 4.7% | 13.4% | 33.2% | 38.6% | 767.8% | 114.0% | 667.9% | 0.1% | 35.2% | – | – | – | |
| -1,900.0% | -3,000.0% | -666.7% | -528.2% | -9,382.4% | -2,225.1% | -520.4% | -117.1% | -281.3% | -220.9% | -146.9% | -115.2% | -187.2% | -181.3% | -327.8% | -424.2% | -1,494.9% | -1,964.0% | -2,628.2% | -2,472.4% | 826.9% | -1,299.6% | -3,328.4% | -1,301.4% | -2,836.2% | -1,110.6% | -175.6% | -260.3% | -195.6% | -471.6% | |
| 100.0% | -200.0% | 33.3% | -53.9% | -629.6% | 32.8% | 204.0% | -373.2% | 157.5% | -5.1% | -7.6% | 37.1% | -1.0% | -3.1% | 92.9% | -54.7% | -210.8% | -114.7% | -378.9% | -178.2% | -7,813.0% | -2,080.9% | -24.4% | -501.2% | -160.3% | -120.8% | 3.7% | -20.2% | 0.3% | -35.1% | |
| -2,000.0% | -3,000.0% | -700.0% | -528.2% | -9,382.4% | -2,408.4% | -735.1% | -313.1% | -448.2% | -229.7% | -160.5% | -137.5% | -251.4% | -267.2% | -303.9% | -379.3% | -1,265.6% | -1,533.8% | -1,870.7% | -1,854.4% | 1,490.8% | -1,114.7% | -3,247.9% | -792.2% | -2,671.3% | -1,104.2% | -178.7% | -240.2% | -195.9% | -436.5% | |
| -3,200.0% | -3,400.0% | -800.0% | -549.4% | -9,553.5% | -2,105.7% | -394.8% | -158.0% | -268.9% | -220.2% | -150.8% | -118.5% | -186.1% | -181.1% | -242.5% | -374.8% | -1,309.4% | -1,208.5% | -2,171.8% | -2,347.1% | -2,407.2% | -2,084.8% | -2,664.0% | -2,427.3% | -3,157.6% | -1,088.2% | -170.6% | -252.5% | -189.2% | -466.8% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.